How will the study progress?
Patients enrolled on our trial will first be monitored for 12 months with no treatment provided. This will create a set of base-line data that tells us how MCDS is affecting them. This base-line will act as their control in the trial. After baseline data is collected, they will then be prescribed carbamazepine for 24 months, and its effect on the condition will be measured.
Recruitment is starting in the UK, where our initial baseline observations will be followed by a period of time to work out the best dose of the drug to give to MCDS patients.